Abstract
Cytochrome P450 3A (CYP3A) is involved in biotransformation of more than half of all drugs currently available. Drug interactions by inhibition of CYP3A are of major interest in patients receiving combinations of drugs. Some interactions with CYP3A inhibitors also involve inhibition of the multidrug export pump, P-glycoprotein. An increasing number of adverse drug reactions might be avoided on the basis of knowledge about CYP3A substrates and inhibitors. This article summarizes some examples of such interactions relevant to gastroenterologists. Serious cases by coadministration of CYP3A inhibitors resulting in acute hepatitis, hypotension, rhabdomyolyis, torsade de pointes, sedation, or ergotism are presented: interactions with azole antifungals (ketoconazole, itraconazole, fluconazole), HIV protease inhibitors (ritonavir, indinavir, saquinavir, nelfinavir), macrolide antibiotics (clarithromycin, erythromycin), and grapefruit juice. In addition, 1 case is reported who presented the highest trough levels of the CYP3A substrate budesonide in serum ever measured. Practitioners have to be aware of the high potential of metabolic drug interactions when they prescribe a CYP3A inhibitor. It is wise to check carefully comedication in patients complaining of side effects with substrates of CYP3A.
Journal Section:
Drug Interactions in Gastroenterology
References
1.
Lin JH, Lu AY: Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361–390.
[PubMed]
2.
Guengerich FP: Update information on human P450s. Drug Metab Rev 2002;34:7–15.
3.
de Wildt SN, Kearns GL, Leeder JS, van den Anker JN: Cytochrome P450 3A: Ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485–505.
[PubMed]
4.
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414–423.
[PubMed]
5.
Wienkers LC: Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discovery. J Pharmacol Toxicol Methods 2001;45:79–84.
6.
Guengerich FP: Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1–17.
[PubMed]
7.
Tanaka E: Clinically important pharmacokinetic drug-drug interactions: Role of cytochrome P450 enzymes. J Clin Pharm Ther 1998;23:403–416.
8.
Thummel KE, Wilkinson GR: In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389–430.
[PubMed]
9.
Zhang Y, Benet LZ: The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001;40:159–168.
10.
Doherty MM, Charman WN: The mucosa of the small intestine: How clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 2002;41:235–253.
11.
Dresser GK, Spence JD, Bailey DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41–57.
[PubMed]
12.
Sagir A, Wettstein M, Oette M, Erhardt A, Häussinger D: Budesonide-induced acute hepatitis in a HIV-positive patient with ritonavir as a co-medication. AIDS 2002;16:1191–1192.
13.
Hempfling W, Grünhage G, Dilger K, Reichel C, Beuers U, Sauerbruch T: Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003;38:196–202.
14.
Jonsson G, Astrom A, Andersson P: Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 1995;23:137–142.
[PubMed]
15.
Como JA, Dismukes WE: Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263–272.
[PubMed]
16.
Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, Maurel P: Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992;6:752–758.
[PubMed]
17.
Bourrie M, Meunier V, Berger Y, Fabre G: Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 1996;277:321–332.
18.
McLachlan AJ, Tett SE: Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. Ther Drug Monit 1998;20:390–395.
19.
Boxenbaum H: Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: Determination of Ki and dangers associated with high clearance drugs in general. J Pharm Pharm Sci 1999;2:47–52.
20.
Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ: Midazolam and triazolam biotransformation in mouse and human liver microsomes: Relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 2000;292:618–628.
21.
Thompson D, Oster G: Use of terfenadine and contraindicated drugs. JAMA 1996;275:1339–1341.
22.
von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI: Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783–791.
[PubMed]
23.
von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI: Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996;16:104–112.
24.
Back DJ, Tjia JF: Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporine by human liver microsomes. Br J Clin Pharmacol 1991;32:624–626.
[PubMed]
25.
Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 1998;28:1203–1253.
26.
Kim RB: Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002;34:47–54.
27.
Tsai WC, Tsai LM, Chen JH: Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc 1997;96:144–146.
28.
Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P: Torsades de pointes after terfenadine-itraconazole interaction. BMJ 1993;306:186.
29.
Zimmermann M, Duruz H, Guinand O, Broccard O, Levy P, Lacatis D, Bloch A: Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992;13:1002–1003.
30.
Moss AJ: The QT interval and torsade de pointes. Drug Saf 1999;21(suppl 1):5–10; discussion 81–87.
31.
Kantola T, Backman JT, Niemi M, Kivistö KT, Neuvonen PJ: Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000;56:225–229.
[PubMed]
32.
Gilad R, Lampl Y: Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 1999;22:295–297.
33.
Vlahakos DV, Manginas A, Chilidou D, Zamanika C, Alivizatos PA: Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine. Transplantation 2002;73:1962–1964.
[PubMed]
34.
Jalava KM, Olkkola KT, Neuvonen PJ: Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997;61:410–415.
35.
Neuvonen PJ, Suhonen R: Itraconazole interacts with felodipine. J Am Acad Dermatol 1995;33:134–135.
[PubMed]
36.
Tailor SA, Gupta AK, Walker SE, Shear NH: Peripheral edema due to nifedipine-itraconazole interaction: A case report. Arch Dermatol 1996;132:350–352.
[PubMed]
37.
Wang JS, Wen X, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT: Midazolam alpha-hydroxylation by human liver microsomes in vitro: Inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacol Toxicol 1999;85:157–161.
38.
Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ: Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997;62:348–354.
39.
Ahonen J, Olkkola KT, Neuvonen PJ: The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam Clin Pharmacol 1996;10:314–318.
40.
Olkkola KT, Backman JT, Neuvonen PJ: Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481–485.
[PubMed]
41.
Odocha O, Kelly B, Trimble S, Murigande C, Toussaint RM, Callender CO: Cost-containment strategies in transplantation: The utility of cyclosporine-ketoconazole combination therapy. Transplant Proc 1996;28:907–909.
42.
Kramer MR, Marshall SE, Denning DW, Keogh AM, Tucker RM, Galgiani JN, Lewiston NJ, Stevens DA, Theodore J: Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990;113:327–329.
43.
Sugar AM, Saunders C, Idelson BA, Bernard DB: Interaction of fluconazole and cyclosporine. Ann Intern Med 1989;110:844.
44.
Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996;334:1011–1017.
[PubMed]
45.
Tseng AL, Foisy MM: Management of drug interactions in patients with HIV. Ann Pharmacother 1997;31:1040–1058.
46.
Eagling VA, Back DJ, Barry MG: Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir, and indinavir. Br J Clin Pharmacol 1997;44:190–194.
[PubMed]
47.
Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, Lee CA: Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998;26:609–616.
48.
Barry M, Gibbons S, Back D, Mulcahy F: Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997;32:194–209.
[PubMed]
49.
Bertz RJ, Granneman GR: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210–258.
[PubMed]
50.
Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, Dennis S, Berg J, Erdman K, Leonard JM, Sun E: Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998;42:2784–2791.
[PubMed]
51.
Hare CB, Vu MP, Grunfeld C, Lampiris HW: Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis 2002;35:e111–e112.
52.
Cheng CH, Miller C, Lowe C, Pearson VE: Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm 2002;59:728–730.
53.
Benveniste O, Longuet P, Duval X, Le Moing V, Leport C, Vilde JL: Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir. Clin Infect Dis 1999;28:1180–1181.
54.
Kato Y, Fujii T, Mizoguchi N, Takata N, Ueda K, Feldman MD, Kayser SR: Potential interaction between ritonavir and carbamazepine. Pharmacotherapy 2000;20:851–854.
[PubMed]
55.
Hugen PW, Burger DM, Brinkman K, ter Hofstede HJ, Schuurman R, Koopmans PP, Hekster YA: Carbamazepine-indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother 2000;34:465–470.
56.
Clay PG, Adams MM: Pseudo-Parkinson disease secondary to ritonavir-buspirone interaction. Ann Pharmacother 2003;37:202–205.
57.
Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI: Alprazolam-ritonavir interaction: Implications for product labeling. Clin Pharmacol Ther 2000;67:335–341.
[PubMed]
58.
Berbel Garcia A, Latorre Ibarra A, Porta Etessam J, Martinez Salio A, Perez Martinez D, Siaz Diaz R, Toledo Heras M: Protease inhibitor-induced carbamazepine toxicity. Clin Neuropharmacol 2000;23:216–218.
59.
Liaudet L, Buclin T, Jaccard C, Eckert P: Drug points: Severe ergotism associated with interaction between ritonavir and ergotamine. BMJ 1999;318:771.
[PubMed]
60.
Cato A 3rd, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R: The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998;63:414–421.
61.
Sheikh AM, Wolf DC, Lebovics E, Goldberg R, Horowitz HW: Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 1999;68:307–309.
[PubMed]
62.
Rossi DR, Rathbun RC, Slater LN: Symptomatic orthostasis with extended-release nifedipine and protease inhibitors. Pharmacotherapy 2002;22:1312–1316.
[PubMed]
63.
Stockley IH: Drug Interactions: A Source Book of Adverse Interactions, Their Mechanisms, Clinical Importance and Management, ed 5. London, Pharmaceutical Press, 2000.
64.
Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdorffer E, O’Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, Cederberg C, Idstrom JP: Eradication of H. pylori using one week triple therapies combining omeprazole with two antimicrobials: The MACH1 Study. Helicobacter 1996;1:138–144.
[PubMed]
65.
Lind T, Megraud F, Unge P, Bayerdorffer E, O’Morain C, Spiller R, Veldhuyzen van Zanten S, Bardhan KD, Hellblom M, Wrangstadh M, Zeijlon L, Cederberg C: The MACH2 Study: Role of omeprazole in eradication of H. pylori with 1-week triple therapies. Gastroenterology 1999;116:248–253.
[PubMed]
66.
von Rosensteil NA, Adam D: Macrolide antibacterials: Drug interactions of clinical significance. Drug Saf 1995;13:105–122.
67.
Rubinstein E: Comparative safety of the different macrolides. Int J Antimicrob Agents 2001;18(suppl 1):71–76.
68.
Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D: Oxidative metabolism of clarithromycin in the presence of human liver microsomes: Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 1997;25:623–630.
69.
Muirhead GJ, Faulkner S, Harness JA, Taubel J: The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol 2002;53(suppl 1):37–43.
70.
Michalets EL: Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84–112.
[PubMed]
71.
Williams D, Feely J: Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343–370.
[PubMed]
72.
Reinoso RF, Sanchez NA, Garcia MJ, Prous JR: Pharmacokinetic interactions of statins. Methods Find Exp Clin Pharmacol 2001;23:541–566.
73.
Bottorf MB: Distinct drug-interaction profiles for statins. Am J Health Syst Pharm 1999;56:1019–1020.
74.
Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999;341:498–511.
[PubMed]
75.
Igel M, Sudhop T, von Bergman K: Metabolism and dry interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001;57:357–364.
76.
Grunden JW, Fisher KA: Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother 1997;31:859–863.
77.
Spach DH, Bauwens JE, Clark CD, Burke WG: Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991;154:213–215.
78.
Ayanian JZ, Fuchs CS, Stone RM: Lovastatin and rhabdomyolysis. Ann Intern Med 1988;109:682–683
79.
Garnett WR: Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995;52:1639–1645.
80.
Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413–428.
[PubMed]
81.
Gruer PJ, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA: Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999;84:811–859.
82.
Lee AJ, Maddix DS: Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001;35:26–31.
[PubMed]
83.
Hayashi Y, Ikeda U, Hashimoto T, Watanabe T, Mitsuhashi T, Shimada K: Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol 1999;22:672–674.
84.
Paar D, Terjung B, Sauerbruch T: Life-threatening interaction between clarithromycin and disopyramide. Lancet 1997;349:326–327.
85.
Iida H, Morita T, Suzuki E, Iwasawa K, Toyo-oka T, Nakajima T: Hypoglycemia induced by interaction between clarithromycin and disopyramide. Jpn Heart J 1999;40:91–96.
[PubMed]
86.
Choudhury L, Grais IM, Passman RS: Torsades de pointes due to drug interaction between disopyramide and clarithromycin. Heart Dis 1999;1:206–207.
87.
Ha HR, Chen J, Freiburghaus AU, Follath F: Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995;39:321–326.
[PubMed]
88.
Cupp MJ, Tracy TS: Cytochrome P450: New nomenclature and clinical implications. Am Fam Physician 1998;57:107–116.
89.
Tjia JF, Colbert J, Back DJ: Theophylline metabolism in human liver microsomes: Inhibition studies. J Pharmacol Exp Ther 1996;276:912–917.
90.
Gray VS: Syncopal episodes associated with cisapride and concurrent drugs. Ann Pharmacother 1998;32:648–651.
[PubMed]
91.
Piquette RK: Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 1999;33:22–26.
[PubMed]
92.
Michalets EL, Williams CR: Drug interactions with cisapride: Clinical implications. Clin Pharmacokinet 2000;39:49–75.
93.
Curel P, Stather R: ADRs and drug safety 1999–2000; in Mann RD, Andrews EB (eds): Pharmacovigilance. Chichester, John Wiley & Sons, 2002, pp 491–502.
94.
Bailey DG, Spence JD, Munoz C, Arnold JM: Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337:268–269.
[PubMed]
95.
Ho PC, Ghose K, Saville D, Wanwimolruk S: Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur J Clin Pharmacol 2000;56:693–698.
96.
Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL: Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996;59:383–388.
[PubMed]
97.
Weber A, Jäger R, Borner A, Klinger G, Vollanth R, Matthey K, Balogh A: Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 1996;53:41–47.
[PubMed]
98.
Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S: Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20–28.
[PubMed]
99.
Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Krähenbühl S: Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998;45:355–359.
[PubMed]
100.
Lilja JJ, Kivistö KT, Neuvonen PJ: Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477–483.
101.
Emilia G, Longo G, Bertesi M, Gandini G, Ferrara L, Valenti C: Clinical interaction between grapefruit juice and cyclosporine: Is there any interest for the hematologists? Blood 1998;91:362–363.
102.
Ducharme MP, Warbasse LH, Edwards DJ: Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485–491.
[PubMed]
103.
Fuhr U: Drug interactions with grapefruit juice: Extent, probable mechanism and clinical relevance. Drug Saf 1998;18:251–272.
[PubMed]
104.
Ameer B, Weintraub RA: Drug interactions with grapefruit juice. Clin Pharmacokinet 1997;33:103–121
[PubMed]
105.
Lundahl J, Regardh CG, Edgar B, Johnsson G: Effects of grapefruit juice ingestion – pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997;52:139–145.
106.
Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, George CF: Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995;40:51–58.
[PubMed]
107.
Edwards DJ, Bernier SM: Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci 1996;59:1025–1030.
108.
Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y: Specific CYP3A4 inhibitors in grapefruit juice: Furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997;7:391–396.
109.
Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB: Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997;25:1228–1233.
110.
He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF: Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998;11:252–259.
[PubMed]
111.
Ubeaud G, Hagenbach J, Vandenschrieck S, Jung L, Koffel JC: In vitro inhibition of simvastatin metabolism in rat and human liver by naringenin. Life Sci 1999;65:1403–1412.
112.
Miniscalco A, Lundahl J, Regardh CG, Edgar B, Eriksson UG: Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther 1992;261:1195–1199.
113.
Guo LQ, Fukuda K, Ohta T, Yamazoe Y: Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 2000;28:766–771.
114.
Wangensteen H, Molden E, Christensen H, Malterud KE: Identification of epoxybergamottin as a CYP3A4 inhibitor in grapefruit peel. Eur J Clin Pharmacol 2003;58:663–668.
[PubMed]
115.
Bailey DG, Arnold JM, Munoz C, Spence JD: Grapefruit juice-felodipine interaction: Mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 1993;53:637–642.
116.
Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follath F: In vitro inhibition of midazolam and quinidine metabolism by flavonoids. Eur J Clin Pharmacol 1995;48:367–371.
117.
Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR: Grapefruit juice-felodipine interaction: Effect of naringin and 6′,7′-dihydroxybergamottin in humans. Clin Pharmacol Ther 1998;64:248–256.
118.
Edwards DJ, Bellevue FH 3rd, Woster PM: Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996;24:1287–1290.
119.
Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, Funck-Brentano C: Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001;70:311–316.
120.
Banfield C, Gupta S, Marino M, Lim J, Affrime M: Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet 2002;41:311–318.
121.
Lundahl J, Regardh CG, Edgar B, Johnsson G: Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol 1995;49:61–67.
[PubMed]
122.
Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ: Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995;58:127–131.
123.
Kantola T, Kivistö KT, Neuvonen PJ: Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63:397–402.
124.
Yee GC, Stanley DL, Pessa LJ, Dalla Costa T, Beltz SE, Ruiz J, Lowenthal DT: Effect of grapefruit juice on blood cyclosporine concentration. Lancet 1995;345:955–956.
[PubMed]
125.
Malhotra S, Bailey DG, Paine MF, Watkins PB: Seville orange juice-felodipine interaction: Comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001;69:14–23.
© 2003 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2003
You do not currently have access to this content.
